Syntax Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Syntax Bio, Inc. - overview
Established
2018
Location
Chicago, IL, US
Primary Industry
Biotechnology
About
Based in Illinois, US, and founded in 2018 by co-founders Brad Merrill, Niko Balanis, and Ryan Clarke, Syntax Bio, Inc. develops and manufactures stem cell-based treatments. In September 2024, Syntax Bio, Inc. raised USD 6 million in venture funding led by investor Astellas Pharma with participation from another investor, Illumina Ventures.
As of September 2024, the company is led by CEO John Flavin. The core technology of Syntax Bio, the Cellgorithm platform, is designed to provide precise control over the differentiation of stem cells into specific cell types. Cellgorithms program cellular differentiation by providing epigenetic instructions that allow for the precise activation of genes sequentially. The technology also employs CRISPR-Cas9 gene-editing techniques to activate and deactivate specific genes as cells develop.
The platform caters for a wide range of therapeutic areas, including immunology, neurology, and regenerative medicine. The company will use the September 2024 funding to utilize additional resources to accelerate its growth.
Current Investors
DCVC, Civilization Ventures, EGB Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.syntax-bio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.